~" Levels of astroprotein (an astrocyte-specific protein found in the cerebrum) were measured by radioimmunoassay in the cerebrospinal fluid (CSF) of 120 patients with intracranial diseases and eight control subjects. The astroprotein level was elevated (above 25 ng/ml) in 13 of 30 cases (43.3%) of glial tumors, nine of 57 cases (15.8%) of nongliomatous intracranial tumors, seven of 33 cases (21.2%) of non-neoplastic intracranial diseases, but in none of the eight control cases. In glioblastoma patients, CSF astroprotein was elevated in eight of 12 cases (66.7%), in three of them to a remarkable degree (above 500 ng/ml). The possible role of this test is briefly discussed, and the mechanism of increase of the astroprotein levels in the CSF considered.
A STROPROTEIN (Ap), so designated by Mori and Morimoto, 8,1~ is a major component of protein in Tay-Sachs disease or 10B fraction protein? It is specific to fibrillary astrocytes in the normal brain, as well as to reactive astrocytes and astrocytoma cells. ~," Glial fibrillary acidic protein (GFAP), detected later by Eng, et al., " ,~ has been shown to be an identical substance. 13 Mori, et al., "'~2 were successful in isolating this protein from human astrocytoma, and developed a radioimmunoassay system by a double-antibody method. The purpose of the present paper is to evaluate the possible role of quantitative analysis of Ap in cerebrospinal fluid (CSF) in the immunochemical diagnosis of brain tumors.
Materials and Methods
We obtained 143 samples of CSF from a series of 120 patients. There were 30 cases with histopathological and/or clinical diagnosis of gliomas, 57 cases with nongliomatous intracranial tumors, and 33 cases with non-neoplastic intracranial diseases. Control CSF samples were obtained from eight patients without clinical or laboratory evidence of intracranial disease. The CSF samples were obtained before surgery, and in six patients (two cases of intraventricular oligodendroglioma, one of frontal astrocytoma, one of thalamic glioblastoma, one of metastatic cerebellar tumor, and one of chronic subdural hematoma), CSF was collected several times postoperatively as well.
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I.--0 w ta 20, These CSF samples were stored at -60~ until assayed.
Methods of purification and radioimmunoassay of Ap have been described elsewhere, TM and only a brief schematic outline is given in Tables 1 and 2 . An antibody titration curve of 125I-Ap with serial dilutions of the anti-Ap serum is shown in Fig. 1 , and a standard coprecipitation inhibition curve with a dilution of antiserum of 1:104 is shown in Fig. 2 . Tables 3 and 4 present Ap levels in CSF obtained preoperatively in patients classified according to clinical and/or histopathological diagnosis. Levels of Ap were under 25 ng/ml in all control cases (eight specimens). On the other hand, 13 of 30 CSF samples (43.3%) obtained from the patients with glial tumors showed increased levels of Ap above 25 ng/ml. In glioblastoma patients, Ap levels in the CSF increased
Results

TABLE 2 Procedures for radioimmunoassay of astroprotein
Step Volume ~5I-astroprotein 100 ~1 standard or sample 100 #1 anti-astroprotein (X10,000) 100 ~1 1st incubation at 4~ for 48 to 72 hrs 1% normal rabbit serum 100 tA anti-rabbit--rG (X15) 100 ~1 2nd incubation at 4~ for 20 hrs centrifuge precipitate count above 25 ng/ml in eight of 12 cases (66.7%). A remarkable increase of CSF Ap (above 500 ng/ml) was observed in one case of anaplastic (malignant) astrocytoma and three cases of glioblastoma. Levels of Ap in the CSF were also elevated above 25 ng/ml in nine of 57 patients (15.8%) with nongliomatous intracranial tumors, and seven of 33 patients (21.2%) with intracranial non-neoplastic diseases, but none showed remarkable increase of Ap in CSF above 500 ng/ml. In patients with intracranial non-neoplastic diseases, it was noted that four of seven patients with hydrocephalus showed increased Ap levels in the CSF. Figure 3 presents the postoperative changes of Ap levels in the CSF of five patients with brain tumors, and of one patient with chronic subdural hematoma. In the tumor patients, removal of an intracerebral tumor was performed in four cases, and biopsy of the tumor was done transventricularly in one case of thalamic glioblastoma. In the case of subdural hematoma, only irrigation of the hematoma through a burr hole was carried out. In the tumor cases, remarkable temporary elevation of Ap levels in the CSF occurred generally in the early postoperative period, followed by gradual decrease, regardless of histopathological diagnosis of the tumors and Ap levels before surgery. On the contrary, the CSF Ap levels following surgery changed only a little in the patient with chronic subdural hematoma. Figure 4 shows the correlation between Ap and total protein levels in CSF in 65 samples in which Ap and total protein contents (Nissl-Esbach's test) were simultaneously determined. It is clear that there is little statistical correlation between them.
Discussion
Recently, attention has been directed largely to the immunochemical diagnosis of tumors, using such special antigenic proteins as alpha-fetoprotein, 1 and carcinoembryonic antigen (CEA)) Astroprotein is not a tumor-specific protein; Ap-containing cells (fibrillary astrocytes) exist even in normal brain tissue. 2,9 However, it has been demonstrated that abundant Ap-rich cells appear and increase in the tissue of glial tumors.
Tests in this study were positive in 43.3% of patients with glial tumors and 66.7% of those with glioblastoma. These percentages are neither very encouraging nor very discouraging. For example, the positive findings for the alpha-fetoprotein test for hepatoma and CEA test for colon cancer, which are T. Hayakawa, et al.
the most used and practical immunochemical tests at present, are 68.2% 1 and 69% to 75%, ~ respectively.
The mechanism that underlies increase of Ap in CSF remains obscure. It was thought that the increase of total protein in CSF can be attributed mainly to the exudation of serum protein, and is not specific to the brain and/or brain tumor tissue. Figure 4 demonstrates that there was poor correlation between total protein and Ap levels in CSF, and that the determination of Ap in CSF may have a different significance from that of CSF total protein.
Jacque, et al., ~ recently investigated glial fibrillary acidic protein (GFAP) content, which is immunologically identical to Ap, in brain tumor tissues by means of the rocket electrophoresis technique. They reported that low levels of GFAP in tumor tissue were always associated with signs of malignancy, such as mitosis and giant or atypical cells, whereas high levels of GFAP were correlated with the presence of well preserved astrocytes. On the contrary, the present findings would indicate that the marked increase of Ap level in CSF may suggest the existence of malignant glial tumor rather than benign glioma. A lack of correlation between tissue content of GFAP and increase of CSF Ap level led us to the working hypothesis that the appearance and increase of Ap in the CSF may be directly related to degenerative and/or destructive processes of Ap-containing cells in the brain rather than to the existence and proliferation of these cells alone. Astroprotein is regarded as a constructive element of glial filament. 8,9,18 It is reasonable to presume that Ap may be released into extracellular space (into CSF space) only when the Ap-containing cells are broken down. It is well known that necrosis and cell degeneration are common and characteristic in glioblastoma tissue, but less in benign gliomas, and almost absent in normal brain tissue. As a result, increase of Ap in CSF may be more remarkable in glioblastoma than in benign glioma and be negligible in normal subjects. This hypothesis is supported by the observation that CSF Ap increased steeply following surgical procedures that were accompanied by a considerable amount of brain (tumor) tissue destruction; however, little change occurred after surgery without brain destruction, that is, in the patient with irrigation of chronic subdural hematoma.
Further studies are necessary, including the correlation between Ap levels in CSF and the size and location of tumors, and between the change of Ap levels in CSF and the course of brain tumors. With these data, it will be possible to estimate the potential value of this test in immunochemical diagnosis of glioma.
